NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Inkwood Research

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research - According to the new market research report launched by Inkwood Research, The Global Opioids Drugs market was valued around $26,373 million in 2018 and is anticipated to hit nearly $32,906 million by 2027, at a CAGR of 2.52%, during 2019-2027
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research

 

NewswireTODAY - /newswire/ - Boston, MA, United States, 2019/10/14 - According to the new market research report launched by Inkwood Research, The Global Opioids Drugs market was valued around $26,373 million in 2018 and is anticipated to hit nearly $32,906 million by 2027, at a CAGR of 2.52%, during 2019-2027.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Browse 36 market data Tables and 25 Figures spread through 147 Pages and in-depth analysis on Global Opioids Drugs market by Product (Buprenorphine, Fentanyl, Hydrocodone, Morphine, Oxycodone, Tramadol, Other products), Application (Pain relief (Cancer pain, Postoperative pain management, Low back pain, Orthopedic, Neuropathic, Fibromyalgia), Anesthesia, Cough suppression, Diarrhea suppression, De-addiction) and by Geography.
This insightful market research report from Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, and Rest of World, the report is a valuable asset for the existing players, new entrants, and the future investors. The study presents detailed market analysis with inputs derived from industry professionals across the value chain.

Opioids Drugs market scenario

The increasing road accidents and surgical procedures, escalating palliative care for patients suffering intensely, usage of abuse-deterrent formulations to restrict the opioid abuse and the growing occurrence of chronic pain are the core drivers that are helping the Global Opioids Drugs market to proliferate further.
The Opioids Drugs market report provides data tables, includes charts and graphs for visual analysis.
Request Free Sample Report for Global Opioids Drugs market by Products, Applications & Geography.

Market Segmentation
On the basis of Product, the Global Opioids Drugs market is segmented as follows:
• Buprenorphine
• Fentanyl
• Hydrocodone
• Morphine
• Oxycodone
• Tramadol
• Other products
On the basis of Application, the Global Opioids Drugs market is segmented as follows:
• Pain relief
oCancer pain
oPostoperative pain management
oLow back pain
oOrthopedic
oNeuropathic
oFibromyalgia
• Anesthesia
• Cough suppression
• Diarrhea suppression
• De-addiction

Report Highlights
- The report provides a detailed analysis of current and future market trends to identify the investment opportunities
- Market forecasts till 2027, using estimated market values as the base numbers
- Key market trends across the business segments, regions and countries
- Key developments and strategies observed in the market
- Market dynamics such as drivers, restraints, opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2027

Companies Profiled
ACURA PHARMACEUTICALS, INC.
ALLERGAN PLC
BIODELIVERY SCIENCES INTERNATIONAL, INC.
CIPHER PHARMACEUTICALS INC.
COLLEGIUM PHARMACEUTICAL, INC.
DAIICHI SANKYO, INC.
EGALET CORP.
HIKMA PHARMACEUTICALS PLC
INDIVIOR INC.
INSYS THERAPEUTICS, INC.
JANSSEN PHARMACEUTICALS, INC.
JOHNSON & JOHNSON
LANNETT CO. INC.
LUPIN LTD.
MYLAN NV
PFIZER INC.
PURDUE PHARMA LP
SANOFI-AVENTIS S.A.
SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
TEVA PHARMACEUTICAL INDUSTRIES LTD.

Related Reports

Atopic Dermatitis Drugs market Global Atopic Dermatitis Drugs market is estimated to grow with approx. 4.77% CAGR during the year 2019-2027.
Pain Management Drugs market - Global Pain Management Drugs market is expected to grow at a 3.88% CAGR during the forecast period.
Hyperphosphatemia Drugs market The Global Hyperphosphatemia Drugs market is expected to grow at a CAGR of 16.13% between the forecast periods of 2019-2027.
Diabetes Drugs market The Global Diabetes Drugs market is expected to grow at a CAGR of 6.50% between the forecast periods of 2019-2027.

About Inkwood Research

Inkwood Research (inkwoodresearch.com) is a leading market & industry research firm offers you consulting services, syndicated & customized market research reports, business analysis & more.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Inkwood Research

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Opioids Drugs market | Diabetes Drugs market
Contact: InkwoodResearch.com 
857-302-4704 sales[.]inkwoodresearch.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Inkwood Research securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Inkwood Research / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Completes Acquisition of Memo Therapeutics AG, Adding First-in-class Asset to Ipsen’s Rare Disease Pipeline
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit BizJobs.com





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)